The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients.
about
Human CMV-specific T-cell responses in kidney transplantation; toward changing current risk-stratification paradigmDirect and Indirect Effects of Cytomegalovirus-Induced γδ T Cells after Kidney TransplantationCMV-Specific CD8 T Cell Differentiation and Localization: Implications for Adoptive TherapiesThe Impact of Infection on Chronic Allograft Dysfunction and Allograft Survival After Solid Organ TransplantationAltered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation.Impact of CMV infection on acute rejection and long-term renal allograft function: a systematic analysis in patients with protocol biopsies and indicated biopsies.Six-month prophylaxis is cost effective in transplant patients at high risk for cytomegalovirus infection.Surveillance of active human cytomegalovirus infection in hematopoietic stem cell transplantation (HLA sibling identical donor): search for optimal cutoff value by real-time PCR.Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes.Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation.IL-6 induced by Staphylococcus aureus infection prevents the induction of skin allograft acceptance in mice.Blood dendritic cell levels associated with impaired IL-12 production and T-cell deficiency in patients with kidney disease: implications for post-transplant viral infections.Valganciclovir: oral prevention and treatment of cytomegalovirus in the immunocompromised host.Long-term outcomes of pre-emptive valganciclovir compared with valacyclovir prophylaxis for prevention of cytomegalovirus in renal transplantation.Primary Cytomegalovirus Infection in Seronegative Kidney Transplant Patients Is Associated with Protracted Cold Ischemic Time of Seropositive Donor OrgansPreformed frequencies of cytomegalovirus (CMV)-specific memory T and B cells identify protected CMV-sensitized individuals among seronegative kidney transplant recipients.Latent cytomegalovirus infection is an independent risk factor for late graft failure in renal transplant recipients.Cytomegalovirus in transplantation - challenging the status quo.Can mTOR inhibitors reduce the risk of late kidney allograft failure?Prevention of allograft tolerance by bacterial infection with Listeria monocytogenes.Immunobiology of human cytomegalovirus: from bench to bedside.Disruption of murine cardiac allograft acceptance by latent cytomegalovirus.Viral infection after renal transplantation: surveillance and management.Cytomegalovirus infection in renal transplantation: clinical aspects, management and the perspectives.The effect of cytomegalovirus infection on acute rejection in kidney transplanted patientsChoice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.Cytomegalovirus infections in solid organ transplantation: a review.Allograft rejection-related gene expression in the endothelial cells of renal transplantation recipients after cytomegalovirus infection.Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients.Defining the risks for cytomegalovirus infection and disease after solid organ transplantation.Valganciclovir for the prevention and treatment of CMV in solid organ transplant recipients.Role of bacterial infections in allograft rejection.Cytomegalovirus-associated renal allograft rejection: new challenges for antiviral preventive strategies.Surrogate markers of infection: interrogation of the immune system.Advances in cytomegalovirus-preventive strategies in solid organ transplantation: defending pre-emptive therapy.A drug safety evaluation of everolimus in kidney transplantation.Pretransplant identification of acute rejection risk following kidney transplantation.Everolimus-based calcineurin-inhibitor sparing regimens for kidney transplant recipients: a systematic review and meta-analysis.Viral surveillance and subclinical viral infection in pediatric kidney transplantation.The efficacy and cost-effectiveness of valacyclovir in cytomegalovirus prevention in solid organ transplantation.
P2860
Q26850340-A901F4DF-573D-44A9-8806-ADBC49D13FBFQ26863724-153EAB3E-983B-4A68-8F57-2F5F8AB3CF16Q28073770-DD6ACF2C-DF3E-40BB-979F-D17956C92388Q28085440-5A06A3A4-C5F5-4E0E-B097-4021C5527851Q30438204-7C7FDD26-3501-4D18-AE19-281174534D4EQ30453768-79301EEA-B696-4CE0-8338-03F235A77648Q33561715-37FE3681-1117-4D38-8F7D-9DDA015775F2Q33591729-B9256BC6-E164-430D-AAB6-60BC266BD8EBQ34077023-DB481442-9F01-4E09-8AB4-C6A2467013E3Q34455315-A825AE48-FE17-407F-B58E-B005A6F85306Q34873028-AD1C135F-B25B-4A88-ACCD-5DBCE0B4F4E2Q35124583-6D1CD702-7739-4097-AADE-9501ADDD1B31Q35871893-A497E52F-0EF7-4040-9CC9-11E6E33569EAQ36200933-EFEC164E-5115-45D8-A830-B8CC4A16164FQ36262672-8C48AA11-DF41-4CDC-9145-938DBC309C8CQ36293963-578A9030-9E23-4BCF-A5A1-4890BE0FA846Q36516318-5A8A254A-6384-496D-B84D-56ADE5C6F39FQ36787493-7DC9DCB0-B692-4F87-A930-A60E3E8B631CQ36884566-74319088-80E5-45C8-92C6-1311B8F26A22Q37003102-449B2751-F886-4903-9BF4-30613D6D7864Q37050965-FE7B05B3-D48D-4C54-8CCA-29A0B27AFC4CQ37060516-F69F35A2-701D-4322-A08F-90A509CF0967Q37097708-BA465F4E-455F-4527-A3D2-AC3EC4265615Q37098580-014D73FB-F708-4433-A049-EC7C148200A6Q37130008-23DAC89B-7A7B-4E25-83F4-41C51314C128Q37318303-C45B3051-7139-4099-A15F-D80F1F8A4A6EQ37359332-598C5121-3180-429F-B17D-C5B0A645D65CQ37411026-62BED3A6-CBD3-49F8-83C2-BF79D930DBF9Q37652611-E072A42D-60A0-4E60-891D-FAE4D3235054Q37680941-3EDEEE77-E45E-4DD8-AE9F-6070E3FAD0BDQ37724248-BEE8D62F-34BA-4C7D-A113-D7D24F494012Q37754716-3449FEE0-42C6-44B2-8500-7C9499339137Q37778827-120D9A51-6D03-4589-A3C1-1B4540570711Q37862743-C1463E7A-F863-471D-B247-983C22C1580BQ37965695-F1316511-8983-4793-9389-316F2167A62EQ38041260-8A21A027-5D7C-4B72-98F1-CD18CDB4BD43Q38151922-A811EE74-9ED2-499E-9AC2-C36F6F98A746Q38229930-4DF90FA2-8914-42B9-8CBC-EFB1933EC24BQ38240085-27531F51-2DC9-4A94-884A-B309B01827D8Q38254037-C8B5C25B-FFA7-4C9C-A3D4-8D69ECDC92E8
P2860
The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The impact of cytomegalovirus ...... in renal allograft recipients.
@en
The impact of cytomegalovirus ...... in renal allograft recipients.
@nl
type
label
The impact of cytomegalovirus ...... in renal allograft recipients.
@en
The impact of cytomegalovirus ...... in renal allograft recipients.
@nl
prefLabel
The impact of cytomegalovirus ...... in renal allograft recipients.
@en
The impact of cytomegalovirus ...... in renal allograft recipients.
@nl
P2093
P2860
P1476
The impact of cytomegalovirus ...... in renal allograft recipients.
@en
P2093
Aksel Foss
Anders Hartmann
Halvor Rollag
Helge Scott
Knut P Nordal
Kåre Osnes
Miklos Degré
Per Fauchald
Solbjørg Sagedal
Ståle Sund
P2860
P304
P356
10.1034/J.1600-6143.2002.20907.X
P407
P577
2002-10-01T00:00:00Z